NCT05152732View on ClinicalTrials.gov

Safety and Tolerability of VGB-R04 in Patients With Haemophilia B

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

December 28, 2021

Primary Completion Date

March 31, 2025

Study Completion Date

December 31, 2025

Conditions
Hemophilia B
Interventions
GENETIC

VGB-R04

A novel, bioengineered adeno-associated viral (AAV) vector carrying human factor IX variant

Trial Locations (1)

300020

RECRUITING

Blood diseases hospital, Tianjin

All Listed Sponsors
lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER